Literature DB >> 25823374

Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.

Nima Sharifi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25823374     DOI： 10.1038/nrurol.2015.66

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

2.  Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.

Authors:  Masuo Yamaoka; Takahito Hara; Takenori Hitaka; Tomohiro Kaku; Toshiyuki Takeuchi; Junzo Takahashi; Satoru Asahi; Hiroshi Miki; Akihiro Tasaka; Masami Kusaka
Journal:  J Steroid Biochem Mol Biol       Date:  2012-01-12       Impact factor: 4.292

3.  Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.

Authors:  Robert Dreicer; David MacLean; Ajit Suri; Walter M Stadler; Daniel Shevrin; Lowell Hart; Gary R MacVicar; Omid Hamid; John Hainsworth; Mitchell E Gross; Yuanjun Shi; Iain J Webb; David B Agus
Journal:  Clin Cancer Res       Date:  2014-01-13       Impact factor: 12.531

4.  Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.

Authors:  Karim Fizazi; Robert Jones; Stephane Oudard; Eleni Efstathiou; Fred Saad; Ronald de Wit; Johann De Bono; Felipe Melo Cruz; George Fountzilas; Albertas Ulys; Flavio Carcano; Neeraj Agarwal; David Agus; Joaquim Bellmunt; Daniel P Petrylak; Shih-Yuan Lee; Iain J Webb; Bindu Tejura; Niels Borgstein; Robert Dreicer
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

Review 5.  Mechanisms of androgen receptor activation in castration-resistant prostate cancer.

Authors:  Nima Sharifi
Journal:  Endocrinology       Date:  2013-09-03       Impact factor: 4.736

6.  Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.

Authors:  Rui Li; Kristen Evaul; Kamalesh K Sharma; Kai-Hsiung Chang; Jennifer Yoshimoto; Jiayan Liu; Richard J Auchus; Nima Sharifi
Journal:  Clin Cancer Res       Date:  2012-07-01       Impact factor: 12.531

7.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

8.  Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Authors:  Juliet Richards; Ai Chiin Lim; Colin W Hay; Angela E Taylor; Anna Wingate; Karolina Nowakowska; Carmel Pezaro; Suzanne Carreira; Jane Goodall; Wiebke Arlt; Iain J McEwan; Johann S de Bono; Gerhardt Attard
Journal:  Cancer Res       Date:  2012-03-12       Impact factor: 12.701

9.  Androgen dynamics and serum PSA in patients treated with abiraterone acetate.

Authors:  C J Ryan; W Peng; T Kheoh; E Welkowsky; C M Haqq; D W Chandler; H I Scher; A Molina
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-03-18       Impact factor: 5.554
  9 in total
  2 in total

Review 1.  Allosteric alterations in the androgen receptor and activity in prostate cancer.

Authors:  Takuma Uo; Stephen R Plymate; Cynthia C Sprenger
Journal:  Endocr Relat Cancer       Date:  2017-09       Impact factor: 5.678

2.  Mechanism of the Dual Activities of Human CYP17A1 and Binding to Anti-Prostate Cancer Drug Abiraterone Revealed by a Novel V366M Mutation Causing 17,20 Lyase Deficiency.

Authors:  Mónica Fernández-Cancio; Núria Camats; Christa E Flück; Adam Zalewski; Bernhard Dick; Brigitte M Frey; Raquel Monné; Núria Torán; Laura Audí; Amit V Pandey
Journal:  Pharmaceuticals (Basel)       Date:  2018-04-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.